Dermatology · Kansas City, KS
NPI
1467555359
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
3901 Rainbow Blvd, Dept of Internal Medicine
Kansas City, KS, 66160
Phone (913) 588-6000
Groups this clinician bills Medicare through
Medicare paid, 2024
$243K
4,892 services
Medicare patients, 2024
466
Average age 77
Drug cost, 2024
$75K
986 prescriptions
Company payments, 2025
$21K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel J Aires was code 17003 (destruction skin lesion), 2,130 times for 208 patients. In total Daniel J Aires billed 4,892 services in 36 codes, and Medicare paid $243K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-12-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 2,130 | 208 | $6.95 | $15K |
| 17000 Destruction Skin Lesion | Office | 614 | 262 | $45.96 | $28K |
| 17110 Destruction Skin Lesion | Office | 574 | 245 | $106.16 | $61K |
| 99213 Office E&M - Established | Office | 531 | 325 | $80.32 | $43K |
| 99212 Office E&M - Established | Office | 285 | 164 | $53.20 | $15K |
| 99214 Office E&M - Established | Office | 124 | 102 | $108.09 | $13K |
| 99203 Office E&M - New | Office | 105 | 105 | $89.79 | $9,428 |
| 17004 Destruction Skin Lesion | Office | 90 | 50 | $160.07 | $14K |
| 11301 Removal or Shaving of Skin Growth | Office | 68 | 59 | $104.57 | $7,111 |
| 11102 Skin Biopsy | Office | 58 | 53 | $77.93 | $4,520 |
| 11300 Removal or Shaving of Skin Growth | Office | 39 | 31 | $72.37 | $2,822 |
| 11306 Removal or Shaving of Skin Growth | Office | 37 | 32 | $109.92 | $4,067 |
| 11302 Removal or Shaving of Skin Growth | Office | 33 | 29 | $123.94 | $4,090 |
| 11311 Removal or Shaving of Skin Growth | Office | 29 | 25 | $123.80 | $3,590 |
| 11310 Removal or Shaving of Skin Growth | Office | 29 | 27 | $87.46 | $2,536 |
By year: 2023 $128K for 2,068 services; 2024 $243K for 4,892 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel J Aires prescribed most often to Medicare patients was Ketoconazole, with 262 prescriptions and refills. In total Daniel J Aires wrote 986 Medicare prescriptions that cost $75K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 262 | 282 | 154 | $4,677 |
| Azelaic Acid Generic | 149 | 159 | 105 | $15K |
| Mupirocin Generic | 106 | 112 | 79 | $701 |
| Triamcinolone Acetonide Generic | 87 | 101 | 61 | $1,092 |
| Ammonium Lactate Generic | 84 | 91 | 51 | $1,254 |
| Clindamycin Phosphate Generic | 45 | 49 | 22 | $770 |
| Hydrocortisone Generic | 40 | 42 | 29 | $225 |
| Clobetasol Propionate Generic | 39 | 39 | 31 | $3,444 |
| Calcipotriene Generic | 32 | 37 | 23 | $4,517 |
| Valacyclovir Valacyclovir Hcl | 29 | 33 | 23 | $457 |
| Imiquimod Generic | 16 | 25 | 13 | $890 |
| Fluorouracil Generic | 12 | 12 | 12 | $832 |
| Metronidazole Generic | 12 | 12 | 11 | $664 |
Brand drugs: 47 claims; generic drugs: 939 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel J Aires $21K ($21K in general payments such as food, travel and fees) from 16 companies. The largest payer was Therakos LLC with $20K.
| Company | Payments | Amount |
|---|---|---|
| Therakos LLC | 16 | $20K |
| Abbvie Inc. ABBV | 5 | $124 |
| Lilly USA, LLC LLY | 4 | $118 |
| UCB, Inc. UCB.BR | 3 | $102 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $65.36 |
| Genzyme Corporation SNY | 2 | $62.55 |
| Incyte Corporation INCY | 2 | $51.01 |
| Organon LLC OGN | 2 | $49.28 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $32.82 |
| Botanix SB Inc | 2 | $31.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.